---
schema_version: "secwatch.filing_event.v1"
accession: "0001005286-26-000018"
form_type: "8-K"
ticker: "LFCR"
cik: "0001005286"
company_name: "LIFECORE BIOMEDICAL, INC. DE"
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:26:26.793402+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# Lifecore Biomedical Q1 revenue $23.2M (-34% YoY), net loss $15.0M, reaffirms FY2026 guidance

## Summary
- Revenue $23.2M, down 34% from $35.2M; gross margin 19% vs 28% prior year.
- Net loss $15.0M ($0.43 loss per diluted share) vs $14.8M loss year ago.
- Adjusted EBITDA $1.0M, down $4.7M from $5.7M; operating expenses cut 52%.
- Signed three new commercial site transfer programs in Q1; reaffirms full-year 2026 guidance.
- Liquidity $38.1M (cash $20.8M, revolver $17.3M); free cash flow $3.6M.

## SEC filing metadata
- accession: 0001005286-26-000018
- form_type: 8-K
- ticker: LFCR
- cik: 0001005286
- company_name: LIFECORE BIOMEDICAL, INC. DE
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.72
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000018/0001005286-26-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1005286/000100528626000018/lndc-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001005286-26-000018
- JSON: https://secwatch.observer/filing/0001005286-26-000018.json
- Plain text: https://secwatch.observer/filing/0001005286-26-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.